Uzbekistan advances pharmaceutical localisation and technology-transfer priorities

Verified facts

• The 6 March 2026 official meeting record states that more than 300 pharmaceutical enterprises operate in Uzbekistan, including 58 directly producing medicinal drugs; it also reports output above UZS 7.3 trillion, a medicines-and-medical-devices market of about US$2.5 billion, and five pharmaceutical industrial zones. These are official aggregate statements, not a verified facility, product or counterparty record.
• The same record acknowledges uneven implementation: it says that no batch was produced in the Jizzakh pharmaceutical zone in the preceding year and that land in the Bostanlyk zone remained unused. This makes implementation and asset-level diligence necessary rather than treating a zone or policy measure as operating capacity.
• The official record describes announced tax, lending, technology-transfer and European-GMP cost-support measures, and refers to localisation lists and Tashkent Pharma Park expansion. Announced measures and responsible-official tasks do not by themselves establish the current effective rule, applicant eligibility, budget availability, certificate result, loan approval or a commercial offer.
• Invest Uzbekistan reports 2025 pharmaceutical production of about US$490 million, exports of about US$250 million, planned sector investment of US$453 million and six specialised pharmaceutical SEZs. It identifies investment themes ranging from medicinal-plant processing to diagnostics, vaccines and medical equipment, but it does not identify a live counterpart, project mandate, land allocation, tender, technology licence or payment route.
• The European Observatory’s independent 2024 health-system review describes a largely public system, a basic publicly financed benefit package that did not yet cover all essential services or medicines, and high out-of-pocket spending. This system context does not validate demand for a particular medicine, device, technology or supplier, but it reinforces the separation between industrial policy, registration, reimbursement and purchasing.